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Although conventional amphotericin B was for many years the drug of choice and remains an important agent against invasive
aspergillosis, reliable susceptibility breakpoints are lacking. Three clinical Aspergillus isolates (Aspergillus fumigatus, Aspergillus
flavus, and Aspergillus terreus) were tested in an in vitro pharmacokinetic-pharmacodynamic model simulating the biphasic
24-h time-concentration profile of free amphotericin B concentrations in human serumwith free peak concentrations (fCmax) of
0.1, 0.3, 0.6, 1.2, and 2.4 mg/liter administered once daily. Drug concentrations were measured with a bioassay, and fungal
growth was monitored for 72 h with galactomannan production. The fCmax/MIC corresponding to half-maximal activity (P50)
was determined for each species, and the percentage of target attainment was calculated for different MICs for the standard (1
mg/kg of body weight) and a lower (0.6-mg/kg) dose of amphotericin B withMonte Carlo simulation analysis. The fCmax/MICs
(95% confidence intervals) corresponding to P50 were 0.145 (0.133 to 0.158), 0.371 (0.283 to 0.486), and 0.41 (0.292 to 0.522) for
A. fumigatus, A. flavus, and A. terreus, respectively. The median percentages of P50 attainment were>88%, 47%, and 0% for A.
fumigatus isolates withMICs of<0.5, 1, and>2 mg/liter, respectively, and>81%, 24%, and 0% and>75%, 15%, and 0% for A.
flavus and A. terreus isolates with MICs of<0.25, 0.5, and>1 mg/liter, respectively. The lower dose of 0.6 mg/kg would retain
efficacy for A. fumigatus, A. flavus, and A. terreus isolates with MICs of<0.25,<0.125, and<0.125 mg/liter, respectively. The
susceptibility, intermediate susceptibility, and resistance breakpoints of<0.5, 1, and>2 mg/liter for A. fumigatus and<0.25,
0.5, and>1 mg/liter for A. flavus and A. terreus were determined for conventional amphotericin B with a pharmacokinetic-
pharmacodynamic model simulating free-drug serum concentrations.
Invasive aspergillosis is a life-threatening disease among patientswith leukemia and bone marrow and solid-organ transplanta-
tion (1). Aspergillus fumigatus is the most common pathogen
causing invasive aspergillosis, accounting for 70% of the cases,
followed by Aspergillus flavus, Aspergillus terreus, and Aspergillus
niger (2). Conventional amphotericin B was for many years the
drug of choice and is still used against invasive aspergillosis. De-
spite its in vitro potent antifungal activity against Aspergillus spp.,
clinical trials have shown that conventional amphotericin B ther-
apy is associated with 60% survival in patients with invasive
aspergillosis (3–6). Although underlying disease, immunosup-
pression, toxicity, and timing of antifungal therapy affect the mor-
tality of these infections, pathogen susceptibility and drug serum
concentrations also represent important contributing factors. In
vivo studies have shown that the best efficacy was achieved when
the maximum concentration of amphotericin B in serum ex-
ceeded 2.4 times the MIC of the A. fumigatus isolate (7). However,
in vitro antifungal susceptibility testing of amphotericin B is chal-
lenged by the lack of reliable susceptibility breakpoints for each
Aspergillus species.
The epidemiological cutoff values 2, 2, and 4 mg/liter for the
CLSI method and 1, 4, and 4 mg/liter for the EUCAST method
were determined for A. fumigatus, A. flavus, and A. terreus, respec-
tively, in order to detect isolates with extreme MICs (8, 9). The
current susceptibility breakpoints for Aspergillus spp. with the
CLSI and EUCAST methodologies are1 mg/liter (9, 10). How-
ever, the supporting clinical and experimental in vivo data are
poor, and no pharmacokinetic-pharmacodynamic (PK-PD) stud-
ies have validated this breakpoint (9). In a retrospective case-con-
trol study of 29 patients, 22/23 patients with isolate MICs of 2
mg/liter died, whereas 6/6 patients with isolate MICs of 1 mg/
liter survived (11). Of note, 5/6 survivors with isolate MICs of1
mg/liter underwent surgery or resolved their neutropenia. In two
other large retrospective studies of 160 and 40 patients, no corre-
lation was found between an Aspergillus MIC of2 mg/liter and
clinical outcome in patients with invasive aspergillosis treated
with conventional amphotericin B (12, 13). Notably, more than
95% of A. fumigatus isolates have MICs of1 mg/liter (8). There-
fore, the majority of the isolates would be considered wild-type
susceptible based on the 1-mg/liter cutoff, while conventional am-
photericin B therapy has been associated with60% of survival in
all clinical trials (3, 4, 14). Furthermore, treatment failure was
observed in patients infected with A. fumigatus and A. flavus iso-
lates with CLSI MICs of 0.25 to 0.5 mg/liter and 1 mg/liter, respec-
tively, when treated with the standard dose of 1 mg/kg of conven-
tional amphotericin B (15, 16). Thus, a clinically relevant and
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useful susceptibility breakpoint for amphotericin B and Aspergil-
lus spp. is warranted.
An in vitro pharmacokinetic-pharmacodynamic model was re-
cently developed for Aspergillus spp. simulating pharmacokinetics
of antifungal drugs (17). This model revealed considerable phar-
macodynamic differences among Aspergillus isolates reflecting
differences in time- and concentration-dependent inhibitory and
fungicidal activity that were not captured by the MIC (18). Using
the same model and simulating multidose human pharmacoki-
netics of voriconazole, in vitro data were predictive of experimen-
tal animal data and clinical outcome for A. fumigatus, enabling the
determination of susceptibility breakpoints and target values for
therapeutic drug monitoring (19).
Therefore, in the present study, we simulated multidose phar-
macokinetics of amphotericin B and studied its activity against A.
fumigatus, A. flavus, and A. terreus. The in vitro PK-PD relation-
ship was described and bridged with human PKs in order to de-
termine susceptibility breakpoints for each species.
MATERIALS AND METHODS
Isolates. Three clinical strains of A. fumigatus (AFM 4215; ATCC MYA-
1163), A. flavus (AFL 113), and A. terreus (AT 137) isolated from patients
with invasive aspergillosis were studied. The MICs of amphotericin B as
determined thrice according to the CLSI broth microdilution method
were 1 mg/liter for all Aspergillus species. The strains were maintained
at70°C in 10% glycerol and cultured twice in Sabouraud dextrose agar
at 30°C for 5 to 7 days. A conidial suspension was prepared in normal
saline with 1% Tween 20. Conidia were counted with a Neubauer cham-
ber in order to obtain a final suspension of 1  103 CFU/ml, and their
concentration was confirmed by quantitative cultures on Sabouraud dex-
trose agar.
Antifungal drug and medium. Pure powder of amphotericin B (Sig-
ma-Aldrich, Bioline, Athens, Greece) was reconstituted at 5,000 mg/liter
in dimethyl-sulfoxide and was stored at 70°C. The medium contained
10.4 g/liter RPMI 1640 with glutamine without sodium bicarbonate (Sig-
ma-Aldrich, St. Louis, MO) and 0.165 M buffer morpholinepropanesul-
fonic acid (MOPS) (Invitrogen, Carlsbad, CA), pH 7.0, with 100 mg/liter
chloramphenicol (Sigma-Aldrich, St. Louis, MO).
In vitro pharmacokinetic-pharmacodynamic model. The in vitro
pharmacokinetic simulation model consisted of (i) a glass beaker contain-
ing 700 ml medium (external compartment [EC]) in which was placed (ii)
a dialysis tube of a 10-ml volume (internal compartment [IC]) made of a
permeable cellulose membrane, which allowed free diffusion of molecules
with a molecular mass of20 kDa, and (iii) a peristaltic pump (Minipuls
Evolution, Gilson, France), which removed the content of EC and added
fresh medium within it at a rate equivalent to drug removal from human
serum (17). The conidial suspension was inoculated in the IC, where it
remained trapped together with the galactomannan (molecular mass of
20 kDa to 60 kDa) produced by the growing mycelia, while nutrients and
drug diffused freely between the IC and EC. The concentration of the
galactomannan increased with fungal growth, as found previously (20).
After inoculation of the IC, the drug was injected into the EC and IC (for
rapid equilibration between the two compartments) every 24 h, and its
concentration declined over time, with a half-life (t1/2) observed in human
serum after intravenous administration of amphotericin B. Because am-
photericin B degrades in vitro at 37C, concentrations were adjusted to
account for the higher clearance. The EC was covered with aluminum foil
in order to minimize light exposure and placed on a heated magnetic
stirrer (37°C). At the beginning of, during, and at the end of each experi-
ment, temperature and flow rate were measured to ensure that they were
at the expected values. All experiments were repeated twice.
Bioassay. The drug levels in the IC were determined by a microbio-
logical agar diffusion method using the strain Paecilomyces variotii ATCC
22319 (18, 21). Specifically, P. variotii conidia at final concentration of 5
104 CFU/ml were inoculated into prewarmed (54°C) RPMI 1640 medium
and MOPS with 15 g/liter agar and poured onto 10- by 10-cm plastic
plates. After solidification of the agar, 1-cm-diameter holes were opened
and filled with 100l of known drug dilutions (range of 0.1 to 8 mg/liter),
as well as 100l of IC samples. The plates were incubated at 37°C for 24 h,
when diameters of inhibition zones were measured. Unknown drug con-
centrations in the IC samples were determined using the standard curve
constructed from known drug concentrations and corresponding diame-
ters of inhibition zones. The diameters of inhibition zones correlated lin-
early with amphotericin B concentrations (R2 0.9). The lowest limit of
detection was 0.1 mg/liter, and the inter- and intraday variations were
10% within the detection range.
Pharmacokinetic analysis. The time-concentration profile of free
amphotericin B observed in human serum after intravenous administra-
tion of 0.6 and 1 mg/kg/day (22, 23) was simulated in the in vitro model.
Thus, the free peak concentrations (fCmax) of 0.1, 0.3, 0.6, 1.2, and 2.4
mg/liter were introduced in the system once daily for 3 days (for A. flavus
and A. terreus, the fCmax of 0.8 and 1 mg/liter were also tested in order to
differentiate their pharmacodynamics). Although fCmax of 1 mg/liter
are not clinically achievable in human serum because of the drug’s solu-
bility limitation, these concentrations were simulated in order to fully
describe the in vitro exposure-effect relationship. The biphasic 24-h time-
concentration profiles of amphotericin B with an alpha phase with a short
half-life of1 h observed within 2 h after drug administration followed by
a beta phase with a longer half-life of 6 to 10 h observed 2 to 24 h after drug
administration were simulated. Amphotericin B concentrations were de-
termined at 0 h, 4 h, 6 h, 8 h, 20 h, 24 h, 44 h, 48 h, and 72 h after the
introduction of the drug in the IC using the bioassay. The data were
analyzed with nonlinear regression based on a two-compartment model
described by the equation C C	e
k	t
 Ce
kt, where k	 and k are the
rate constants, C	 and C are the y intercepts for alpha and beta, respec-
tively, and C is the concentration at a given time t. The half-lives of alpha
and beta phases were calculated using the equations t1/2,	  k	/ln(2) and
t1/2,  k/ln(2), respectively.
Determination of fungal growth. Fungal growth in the IC was as-
sessed in samples of 100l at regular time intervals by determining galac-
tomannan production using an enzyme-linked immunosorbent assay
(ELISA) (Platellia; Bio-Rad, Athens, Greece). Samples were diluted with
200 l saline in order to reach the final volume of 300 l before process-
ing. Results were expressed as a galactomannan index (GI) according to
the manufacturer’s instructions. Galactomannan levels were also deter-
mined in the EC in order to ensure that no galactomannan escaped from
the IC.
Pharmacodynamic analysis. In vitro pharmacodynamics of each am-
photericin B dose and Aspergillus species were determined based on the
GI-time relationship analyzed with the Emax model: E  Emin 
 Emax 
T/(T
T50
), where E is the GI (dependent variable), Emax and Emin are
the maximum and minimum GI, respectively, T is the incubation time
(independent variable), T50 is the time corresponding to 50% of the Emax,
and  is the slope of the curve. As shown previously, the parameters Emax,
, and T50 describe the extent, rate, and time of galactomannan produc-
tion, respectively, whereas the area under the galactomannan index-time
curve (AUCGI) is a surrogate marker of fungal growth capturing any dif-
ferences in extent, rate, and time of antifungal activity. The higher the
AUCGI, the greater is the fungal growth over time. The area under the
galactomannan index-time curve (AUCGI) was calculated for each
amphotericin B dose and drug-free control. The percentage of fungal
growth at each dose was calculated based on the AUCGI of each dose
divided by the AUCGI of the drug-free growth control. The percent
growth-fCmax/MIC relationship was analyzed with the Emax model: E 
Emin
 Emax P
/(P 
 P50
), where E is the percent growth (dependent
variable), Emax and Emin are the maximum and minimum percent growth,
respectively, P is the PK-PD index fCmax/MIC (independent variable), P50
is the fCmax/MIC corresponding to 50% of Emax, and  is the slope of the
curve. In addition, the fCmax/MIC corresponding to near-maximum an-
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tifungal activity (i.e., 80% inhibition or 20% growth; P80) was calculated
for each Aspergillus species. The 95% confidence interval (CI) of the pa-
rameters P50 and P80 obtained with the regression analysis was used as an
estimate of both biological and experimental variation as previously de-
scribed (19).
Monte Carlo simulation. In order to bridge the in vitro data with
human PKs, the steady-state fCmax of 1,000 patients receiving the standard
dose of amphotericin B, 1 mg/kg intravenously, were simulated with
Monte Carlo analysis. This dosage resulted in steady-state total maximum
concentrations in human serum (tCmax) of 2.83  1.17 mg/liter, respec-
tively (23), which corresponds to free maximum concentrations (fCmax)
of 0.14 0.06 mg/liter based on the 95% protein binding rate of ampho-
tericin B previously found at these concentrations (24). The percentage of
patients with fCmax/MIC exceeding the median, upper, and lower 95% CI
limits of the PK-PD targets P50 and P80 were calculated for different MICs
and for each Aspergillus species.
Because the dose of 1 mg/kg is associated with significant toxicity,
Monte Carlo analysis was also performed for a lower dose of conventional
amphotericin B, 0.6 mg/kg, used in clinical practice. This dose resulted
in a serum tCmax of 1.43  0.2 mg/liter, corresponding to an fCmax of
0.0715  0.01 mg/liter (22, 24). The median, upper, and lower 95% CI
limits of percentage of P50 target attainment were calculated for each
species and for different MICs. Finally, because trough levels (Cmin) are
clinically easier obtained than Cmax levels, the trough levels were associ-
ated using linear regression analysis with Cmax concentrations in the in
vitro PK-PD model.
Statistical analysis. All analysis was performed with the Prism 5.01
software (GraphPad Inc., La Jolla, CA). All Emax models were globally
fitted to the data, with Emax and Emin shared among data sets. Compari-
sons between Emax model parameters among Aspergillus species were as-
sessed using the extra sum-of-squares F test. Monte Carlo analysis was
performed with the random function of an Excel spreadsheet (MS Office
97). A P value of0.05 was considered statistically significant.
RESULTS
Pharmacokinetic analysis. The time-concentration profiles of
amphotericin B doses are shown in Fig. 1. The calculated fCmax in
the IC were within20% of the target fCmax of 0.1, 0.3, 0.6, 0.8, 1,
1.2, and 2.4 mg/liter. The half-lives of alpha and beta phases were
0.2 to 2 h and 10 to 17 h, respectively.
Pharmacodynamic analysis. Fungal growth was progressively
inhibited at higher concentrations of amphotericin B. The GI-
time curves followed a sigmoid pattern described well by the Emax
model (R2 0.82), and they were characterized by the same Emax
but different slopes and T50s for the different doses of amphoter-
icin B and Aspergillus species tested (Fig. 2). Complete inhibition
of fungal growth was found for A. fumigatus with an amphotericin
B fCmax of0.3 mg/liter, while for A. flavus and A. terreus, com-
plete inhibition was obtained with an amphotericin B fCmax of
0.8 mg/liter. In particular, the percentages of fungal growth at
fCmax of 0.1, 0.3, and 0.6 mg/liter were 97%, 78%, and 74% for A.
flavus and 96%, 82%, and 67% for A. terreus, respectively.
The fCmax/MIC relationship followed a sigmoid pattern (global
R2 0.96) for all three species (Fig. 3). The fCmax/MIC (95% CI)
FIG 1 Multidose pharmacokinetics of amphotericin B in the in vitro model
with different fCmax and t1/2 of 0.2 to 2 h and 10 to 17 h for alpha and beta
phases, respectively. Coefficient of variations was 15% between two repli-
cates.
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FIG 2 Multidose pharmacodynamic analysis of simulated amphotericin B doses with fCmax of 0.1, 0.3, 0.6, 0.8, 1, 1.2, and 2.4 mg/liter against A. fumigatus, A.
flavus, and A. terreus isolates with a modal CLSI MIC of 1 mg/liter as determined by the galactomannan index in the in vitro PK-PD model.
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associated with 50% growth for A. fumigatus was 0.145 (0.133 to
0.158), which was statistically significantly lower than the corre-
sponding fCmax/MIC of A. flavus (0.371; 0.283 to 0.486) and A.
terreus (0.41; 0.292 to 0.522) (P 0.001). The fCmax/MICs corre-
sponding to near maximal activity (20% growth) were 0.188
(0.166 to 0.213), 0.474 (0.362 to 0.655), and 0.545 (0.376 to 0.714)
for A. fumigatus, A. flavus, and A. terreus, respectively.
Monte Carlo simulation analysis. Monte Carlo simulation
analysis of 1,000 patients receiving the standard amphotericin B
dose of 1 mg/kg resulted in mean tCmax standard deviation (SD)
values of 2.8 1.2 mg/liter (fCmax SD of 0.14 0.06 mg/liter).
These values are close to the target values previously found in
clinical studies (23). The percentage of patients attaining the
PK-PD target (fCmax/MIC) associated with half-maximal (P50) ac-
tivity is shown in Fig. 4. Higher-than-75% and lower-than-15%
P50 target attainment was found for A. fumigatus isolates with
MICs of 0.5 and 2 mg/liter and for A. flavus and A. terreus
isolates with MICs of 0.25 and 1 mg/liter. In particular, the
median (range) percentages of target attainment for A. fumigatus,
A. flavus, and A. terreus isolates with a MIC of 1 mg/liter were 47%
(39 to 57%), 0% (0 to 0%), and 0% (0 to 0%) and with a MIC of
0.5 mg/liter were 88% (87 to 90%), 24% (5 to 50%), and 15% (2 to
46%), respectively. The percentages of P80 target attainment for A.
fumigatus, A. flavus, and A. terreus isolates with a MIC of 1 mg/liter
were 22%, 0%, and 0%, respectively (data not shown).
For the lower amphotericin B dose of 0.6 mg/kg, a 98% P50
target attainment was found for MICs of 0.25, 0.125, and
0.125 mg/liter for A. fumigatus, A. flavus, and A. terreus, respec-
tively (Fig. 4). A linear correlation (r2 0.98) was found between
the Cmin and the Cmax levels in the in vitro model with a slope of
0.20  0.03, indicating that Cmin levels correspond to 1/5 of the
Cmax concentrations, as previously found in humans (22, 23).
DISCUSSION
The multidose pharmacodynamic study of amphotericin B using
an in vitro pharmacokinetic-pharmacodynamic model that simu-
lated free serum amphotericin B concentrations revealed differ-
ences among the three Aspergillus species. Complete growth inhi-
bition was observed at an fCmax of0.3 mg/liter for A. fumigatus
and0.8 mg/liter for A. flavus and A. terreus despite their identi-
cal MIC values. The fCmax/MICs (95% CI) corresponding to near-
maximal activity were 0.188 (0.166 to 0.213), 0.474 (0.362 to
0.655), and 0.545 (0.376 to 0.714) for A. fumigatus, A. flavus, and
A. terreus, respectively. These differences are in agreement with
our previous study where single-dose pharmacokinetics and a
higher initial inoculum were used, providing better discrimina-
tion of the in vitro activity of amphotericin B against the three
species (18). The observed differences among the three species
were attributed to the fast inhibitory action and increased killing
rate against A. fumigatus, a slower inhibitory action and reduced
killing efficiency against A. flavus, and the slowest inhibitory ac-
tion and no killing against A. terreus (18).
The PK-PD target of near maximal antifungal activity found in
the present study against A. fumigatus is in agreement with that
previously obtained in a murine neutropenic model of experi-
mental pulmonary aspergillosis demonstrating that the tCmax/
MIC of 2.4 was associated with near-maximal survival (7).
Considering that the free-drug percentage of conventional am-
photericin B in mouse serum corresponded to 7.4% (25), the in
vivo fCmax/MIC corresponds to 0.178, which is very close to the in
vitro fCmax/MIC of 0.188 found in the present study. In addition,
in neutropenic murine models of experimental aspergillosis, the
dose of 5 mg/kg of amphotericin B was associated with 80%
survival against A. fumigatus isolates with MICs of 0.5 and 1 mg/
liter and40% against A. terreus and A. flavus isolates with MICs
FIG 3 Multidose exposure-efficacy relationship of amphotericin B against
each Aspergillus species with modal CLSI MICs of 1 mg/liter for A. fumigatus,
A. flavus, and A. terreus in the in vitro PK-PD model simulating amphotericin
B human serum levels based on the increasing amphotericin B fCmax (maxi-
mum concentration) and the galactomannan index as a marker of fungal
growth.
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FIG 4 The percentage of patients attaining the PK-PD target associated with half-maximal activity (P50) for A. fumigatus, A. flavus, and A. terreus isolates with
different MICs based on the Monte Carlo analysis simulating 1,000 patients treated with 1 or 0.6 mg/kg of conventional amphotericin B. Error bars represent the
range of percentage of target attainment for the upper and lower 95% CI limit of the P50 target.
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of 1 to 2 mg/liter (26 to 29). The dose of 5 mg/kg, which corre-
sponds to a tCmax around 2.5 mg/liter (i.e., fCmax of 0.185 mg/liter)
in mouse serum (7, 30), would attain the PK-PD targets deter-
mined in the present study for A. fumigatus but not for A. terreus
and A. flavus isolates. However, there are many confounding fac-
tors, like immunosuppression, type and severity of infection, dos-
ing regimens, time of initiation of antifungal therapy, pharmaco-
kinetic variation, and in vitro susceptibility testing, that prohibited
direct in vitro-in vivo correlation (31 to 33). These factors can be
simulated in the present model in order to study the impact of host
defense cells, delayed drug administration, and disease progres-
sion on the magnitude of the PK-PD parameter.
The present in vitro model indicated that the standard dose of
1 mg/kg of amphotericin B is associated with 47% target attain-
ment using a half-maximum activity PK-PD target (P50) and 22%
using a near-maximum activity PK-PD target (P80) for Aspergillus
fumigatus isolates with an amphotericin B MIC of 1 mg/liter. This
is in agreement with a previous retrospective study where the
MICs of 274 clinical Aspergillus isolates from transplant recipients
with proven or probable invasive aspergillosis were analyzed to-
gether with survival after 6 and 12 weeks of treatment (34). In that
study, isolates with amphotericin B MICs of 1 mg/liter belonging
mainly to Aspergillus fumigatus species were associated with 45%
6-week and 25% 12-week survival, in agreement with the percent-
ages of P50 and P80 target attainment found in the present study,
respectively.
The choice of the in vitro PK-PD target (P50 or P80) for corre-
lating in vitro data with clinical outcome remains controversial.
The percentage of P80 target attainment was comparable to 12-
week survival, whereas the percentage of P50 target attainment was
comparable to 6-week survival. High serum drug exposure (P80)
may result in high concentrations at the site of infection and/or
fungicidal actions that will likely produce a long-lasting effect (12-
week survival) compared to the lower drug exposure (P50) that
will produce a short-lasting effect (6-week survival). However,
since most deaths during the second 6-week period of 12-week
therapy were attributed to causes other than invasive aspergillosis,
albeit with some uncertainty, the 6-week survival endpoint was
suggested to be the preferable endpoint to judge the effectiveness
of antifungal therapy (35). Because the percentage of P50 target
attainment found by Monte Carlo analysis of the present study for
A. fumigatus isolates with an amphotericin B MIC of 1 mg/liter
was correlated with the 6-week survival found previously in a ret-
rospective study of the MIC-clinical outcome correlation for the
same isolates (34), we used the P50 endpoint to bridge the in vitro
PK-PD data with human PK in Monte Carlo analysis and to de-
termine susceptibility breakpoints.
An important assumption when bridging in vitro concentra-
tions to serum PK is that the serum concentrations correspond to
the tissue concentrations at the site of infection, which is the lung
in the case of invasive pulmonary aspergillosis. In vivo pharmaco-
kinetic data of conventional amphotericin B in mice showed that
although the tCmax in the lung was lower than the tCmax in serum
(3.33 and 4.58 mg/liter, respectively), the fCmax values were similar
(0.33 and 0.34 mg/liter, respectively) based on the different degree
of protein binding in the lung (10%) compared to that in serum
(7.4%) (30). In two clinical studies, a wide range of amphotericin
B lung concentrations (0.1 to 23.3 g/g) were detected with high-
performance liquid chromatography (HPLC) in patients with
mean concentrations of 11.29 and 5.29 g/g (36, 37). However,
only a small (1.5% to 30%) proportion of HPLC-detected ampho-
tericin B was bioactive, and an even smaller proportion of the
latter (10%) corresponded to free amphotericin B (36, 37).
Thus, the free concentration of amphotericin B in the lung may be
similar to the free drug concentrations in human serum. For other
sites of infections where amphotericin B penetrates poorly (e.g.,
brain), the tissue-to-serum ratio should be taken into account.
Microdialysis experiments may provide better estimates of free
amphotericin B in tissues (38).
The results obtained by the Monte Carlo analysis point to the
following breakpoints for susceptibility, intermediate susceptibil-
ity, and resistance: 0.5, 1, and 2 for A. fumigatus and 0.25,
0.5, and1 for A. flavus and A. terreus. Based on these breakpoints
and previous epidemiological susceptibility data, 40% of A. fu-
migatus, 90% of A. flavus, and 98% of A. terreus isolates would be
considered nonsusceptible (8). In a randomized prospective clin-
ical trial of invasive aspergillosis mainly by A. fumigatus, conven-
tional amphotericin B was associated with 42% 6-week mortality,
which is in agreement with the 40% of A. fumigatus isolates esti-
mated in the present study being nonsusceptible (3). Further-
more, in a review paper of 60 clinical cases of invasive A. terreus
infections published from 1966 to 2003, 28 cases were treated with
conventional amphotericin B, and the mortality rate was 96%
(27/28), which is also in agreement with the 98% of A. terreus
isolates estimated in the present study being nonsusceptible (39).
Finally, in a cohort study of 11 cases of invasive A. flavus infections
treated only with conventional amphotericin B, the mortality rate
was 81% (9/11), in agreement with the 90% of A. flavus isolates
estimated in the present study being nonsusceptible (16). Inter-
estingly, in the latter study, all patients with A. flavus isolate MICs
of1 mg/liter died. These clinical data provide further support of
the breakpoints determined in the present PK-PD model.
In order to maximize the efficacy and minimize the toxicity of
conventional amphotericin B treatment, one could increase or
decrease the dose based on the MIC of isolated pathogens or epi-
demiological data of each center. Thus, for a small number of A.
fumigatus, A. flavus, and A. terreus strains with MICs of 0.25,
0.125, and 0.125 mg/liter, respectively, the lower dose of 0.6
mg/kg would retain efficacy of the 1-mg/kg dosage but reduce its
toxicity. The 0.6-mg/kg dose was associated with 30% renal tox-
icity compared to 50% renal toxicity associated with the
1-mg/kg dose of amphotericin B (5, 40). For isolates with inter-
mediate susceptibility, therapeutic drug monitoring (TDM) with
the goal to attain the PK-PD target could increase the efficacy of
the standard dose of 1 mg/kg of amphotericin B as previously
suggested (41). Since TDM is easier performed using trough
(Cmin) levels than Cmax levels, the fCmin/MIC (tCmin/MIC) ratios
based on the in vitro model were 0.029 (0.58), 0.074 (1.48), and
0.082 (1.64) for A. fumigatus, A. flavus, and A. terreus, respectively.
Since in vivo amphotericin B is bound by tissue and slowly re-
leased, accounting for the prolonged (serum) terminal elimina-
tion half-life of the drug, the correlation between fCmin and fCmax
may be clinically relevant only for the first few days of therapy.
However, the unavoidable toxicity of conventional amphotericin
B, which often results in drug discontinuation, will be the limiting
factor even for susceptible isolates, limiting the use of conven-
tional amphotericin B, in agreement with the ECIL guidelines for
the management of invasive aspergillosis (42). Therefore, lipid
formulations of amphotericin B could be used efficiently even for
isolates with reduced susceptibility to conventional amphotericin
Elefanti et al.
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B, as previously shown in an animal model infected by an A. fu-
migatus isolate with a MIC of 1 mg/liter (43). Lipid formulations
can safely deliver high concentrations of amphotericin B in the
fungal target and at the site of infection (44).
In conclusion, a PK-PD model was used to simulate free am-
photericin B serum concentrations and to study the in vitro activ-
ity against three Aspergillus species. The PK-PD targets were 0.145,
0.371, and 0.41 fCmax/MIC for A. fumigatus, A. flavus, and A. ter-
reus, respectively, and the susceptibility breakpoints derived were
0.5, 1, and2 mg/liter for A. fumigatus and0.25, 0.5, and1
mg/liter for A. flavus and A. terreus. The suggested breakpoints are
substantiated with results obtained from previously published
clinical studies of invasive aspergillosis.
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